Iterum Therapeutics plc (ITRMF) EPS (Basic) (2017 - 2025)

Iterum Therapeutics' EPS (Basic) history runs 9 years deep, the most recent figure standing at -$0.2 for Q3 2025.

• In Q3 2025, EPS (Basic) rose 35.52% year-over-year to -$0.2; the TTM figure through Sep 2025 stood at -$0.59 (up 61.38% YoY), while the FY2024 annual figure was -$1.26, up 57.52% from the prior year.
• EPS (Basic) for Q3 2025 stood at -$0.2, down from -$0.16 in the prior quarter.
• The five-year high for EPS (Basic) was $0.04 in Q2 2021, with the low at -$2.38 in Q3 2022.
• The 5-year median for EPS (Basic) is -$0.3 (2024), against an average of -$0.45.
• The sharpest annual moves came in 2021 and 2022: EPS (Basic) jumped 105.4% in 2021, then plunged 11722.6% in 2022.
• Iterum Therapeutics' EPS (Basic) stood at -$0.03 in 2021, then tumbled by 1524.95% to -$0.42 in 2022, then slumped by 129.27% to -$0.95 in 2023, then surged by 64.96% to -$0.33 in 2024, then surged by 41.33% to -$0.2 in 2025.
• Business Quant data shows ITRMF's EPS (Basic) at -$0.2 in Q3 2025, -$0.16 in Q2 2025, and -$0.14 in Q1 2025.